Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Hepatitis b reactivation? 684 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 684 reports of Hepatitis b reactivation have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.8% of all adverse event reports for DOXORUBICIN.

684
Reports of Hepatitis b reactivation with DOXORUBICIN
0.8%
of all DOXORUBICIN reports
270
Deaths
171
Hospitalizations

How Dangerous Is Hepatitis b reactivation From DOXORUBICIN?

Of the 684 reports, 270 (39.5%) resulted in death, 171 (25.0%) required hospitalization, and 34 (5.0%) were considered life-threatening.

Is Hepatitis b reactivation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 684 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Hepatitis b reactivation?

RITUXIMAB (914) CYCLOPHOSPHAMIDE (801) VINCRISTINE (641) PREDNISONE (583) PREDNISOLONE (465) LAMIVUDINE (308) METHOTREXATE (305) DEXAMETHASONE (293) ETOPOSIDE (213) TENOFOVIR DISOPROXIL (162)

Which DOXORUBICIN Alternatives Have Lower Hepatitis b reactivation Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Hepatitis b reactivation Reports All Drugs Causing Hepatitis b reactivation DOXORUBICIN Demographics